Opus Genetics and Global RDH12 Alliance Announce Strategic Partnership to Advance Gene Therapy for Childhood Blindness
Reuters
Jul 23
<a href="https://laohu8.com/S/IRD">Opus Genetics</a> and Global RDH12 Alliance Announce Strategic Partnership to Advance Gene Therapy for Childhood Blindness
Opus Genetics Inc., a clinical-stage biopharmaceutical company, has announced a strategic partnership with the Global RDH12 Alliance to advance the development of its gene therapy program, OPGx-RDH12, aimed at treating vision loss associated with RDH12-associated Leber congenital amaurosis (RDH12-LCA). The collaboration is designed to accelerate the transition of this promising therapy from the laboratory to clinical settings. The Alliance will contribute up to $1.6 million towards the development of the OPGx-RDH12 program, incorporating a risk-sharing structure and performance-based milestones. The partnership plans to file an Investigational New Drug $(IND.AU)$ application with the U.S. FDA by late 2025. Results from the ongoing development have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-026853), on July 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.